lvrna009
VaccineexperimentalCOVID-19
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 31, 2021 (NCT05364047)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05682638 | Phase 3 | Jan 30, 2023 | AIM Therapeutics Inc., Government of China |
| NCT05428592 | Phase 3 | Dec 31, 2022 | Government of China |
| NCT05352867 | Phase 2 | Mar 16, 2022 | Government of China |
| NCT05364047 | Phase 1 | Jul 31, 2021 | Central South University, Government of China, Hangzhou Hospital of Traditional Chinese Medicine, Yuncheng Central Hospital |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 4 | 3 | 2021 |
| AIM Therapeutics Inc. | For profit | 1 | 0 | 1 | 2023 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hangzhou Hospital of Traditional Chinese Medicine | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Yuncheng Central Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1